Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies

被引:2
|
作者
Fujisawa, Takuo [1 ]
Tsuta, Koji [2 ]
Yanagimoto, Hiroaki [3 ]
Yagi, Masao [1 ]
Suzuki, Kensuke [1 ]
Nishikawa, Kenji [4 ]
Takahashi, Masaru [4 ]
Okada, Hisatake [4 ]
Nakano, Yasushi [4 ]
Iwai, Hiroshi [1 ]
机构
[1] Kansai Med Univ, Dept Otolaryngol Head & Neck Surg, Osaka 5731010, Japan
[2] Kansai Med Univ, Dept Pathol & Lab Med, Osaka 5731010, Japan
[3] Kansai Med Univ, Dept Surg, Osaka 5731010, Japan
[4] Kon Minolta Inc, Corp R&D Headquarters, Bio Adv Technol Div, Bio Syst Dev Grp, Tokyo 1918511, Japan
关键词
programmed death ligand-1; digital immunostaining; ELISA; nCounter; EXPRESSION; PEMBROLIZUMAB;
D O I
10.3892/mco.2019.1801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 50 条
  • [31] PD-L1 Expression in Small Cell Lung Carcinoma: An Immunohistochemical Analysis of 26 Cases Using Two Anti-PD-L1 Antibodies
    Illei, Peter B.
    Forde, Patrick
    Hann, Christine
    Yang, Stephen
    Kelly, Ronan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S360 - S360
  • [32] Immunohistochemical study of the PD-1/PD-L1 pathway in cutaneous lupus erythematosus
    Kiraly, Z.
    Szepesi, A.
    Sebestyen, A.
    Kuroli, E.
    Rencz, F.
    Toth, B.
    Bokor, L.
    Szakonyi, J.
    Medvecz, M.
    Hidvegi, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S191 - S191
  • [33] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
  • [34] Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
    Kiraly, Zsofia
    Szepesi, Agota
    Sebestyen, Anna
    Kuroli, Eniko
    Rencz, Fanni
    Toth, Bela
    Bokor, Laura
    Szakonyi, Jozsef
    Medvecz, Marta
    Hidvegi, Bernadett
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28
  • [35] An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients
    Rebelatto, Marlon C.
    Mistry, Amita
    Sabalos, Constantine
    Schechter, Nicole
    Walker, Jill
    Midha, Anita
    Steele, Keith E.
    Robbins, Paul B.
    Li, Xia
    Shi, Li
    Blake-Haskins, John A.
    Ibrahim, Ramy A.
    Richman, Laura
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [36] Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
    Wang, Zhijie
    Yuan, Lin
    Liao, Xiaotong
    Guo, Xia
    Chen, Jianjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) : 6027 - 6043
  • [37] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou, Markella
    Zarganes-Tzitzikas, Tryfon
    Magiera-Mularz, Katarzyna
    Holak, Tad A.
    Domling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
  • [38] A comparison of monoclonal antibodies against murine PD-1 and PD-L1
    Bu, Melissa Tian
    Yuan, Long
    Klee, Alyssa
    Freeman, Gordon J.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [39] Identification of novel antagonistic anti-PD-1 antibodies that are non-blocking of the PD-1/PD-L1 interaction
    Fenwick, Craig
    Pellaton, Celine
    Farina, Alex
    Radja, Navina
    Pantaleo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Ventana PD-L1 (SP142) Assay
    McGill, Rachel
    Michail, Ramez
    Miller, Brianne
    Milton, Erica
    Musyoka, Agnes
    Musyoka, Rhoda
    O'Conner, Jada
    Ogunnaike, Morenike
    Omeke, Soteria
    Franklin, Gallop
    Honeywell, Marlon S.
    US PHARMACIST, 2022, 47 (10) : 42 - 44